Internists’ deprescribing behavior for proton pump inhibitor therapy: a qualitative study based on the theoretical domains framework internists’ deprescribing behavior for PPI therapy Authors: Beyza Nur Ataoğlu, Betul Okuyan, Rabia Yaren Şahin, Beril Koçak, Ayberk Denizli, Asiye Sena Anli, Pınar Ay Published: 2026 ABSTRACT BackgroundProton pump inhibitors (PPIs) are among the most frequently prescribed medications. However, they are often used inappropriately and may cause adverse effects in long-term use. This study aimed to explore internists’ beliefs, attitudes and behaviors regarding deprescribing PPIs in Türkiye, by using the Theoretical Domains Framework (TDF).MethodsThis qualitative study was conducted at a university hospital in Türkiye. Data were collected through face-to-face, in-depth interviews conducted in March-April 2023. The participants were selected through convenience sampling from among the residents and specialists working in the internal medicine department. A semi-structured interview guide, including two vignettes, was used. The data were evaluated using thematic analysis in Atlas.ti program.ResultsA total of 12 participants (10 residents and two specialists) participated in the study. Internists’ behaviors related to deprescribing were mapped to 12 TDF domains including barriers (environmental context and resources, reinforcement, social influences, optimism/pessimism and emotions, social/professional role and identity, and knowledge and skills, beliefs about consequences) and enablers (intention and goals, memory, attention, and decision-making processes, beliefs about consequences). Despite the challenges posed by a fragmented healthcare system, heavy workload, poor coordination among providers, and patients’ strong expectations of PPIs as “rescue” drugs, the participants still expressed an intention to deprescribe.ConclusionsThis study highlights the need for systemic changes to improve deprescribing practices for PPIs in Türkiye. To promote deprescribing, appropriate behavior change techniques and implementation strategies should be identified and evaluated to ensure integrated care, evidence-based guidelines, and patient-centered practice.Clinical trial numberNot Applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12913-026-14803-9. Background Proton pump inhibitors (PPIs) revolutionized the treatment of gastric acid-related diseases with the introduction of omeprazole in 1989. Since then, PPIs have become one of the most widely prescribed medications globally [33]. These medications are essential in the management of conditions such as gastroesophageal reflux disease, esophagitis, peptic ulcer disease, and Helicobacter pylori infection [34] and preventing gastrointestinal bleeding (or stress ulcers) in critically ill patients [41]. A significant proportion of PPIs prescriptions are issued without appropriate indications. Even when prescribed appropriately, some patients continue using them for extended periods - or even lifelong - despite clinical guidelines recommending discontinuation [26, 36]. While short-term use of PPIs at appropriate doses is generally safe, long-term use has been associated with adverse effects including pneumonia, Clostridioides difficile infection, vitamin B12 deficiency, hypomagnesemia, iron deficiency, and impaired calcium absorption leading to bone fractures [13, 23]. Other potential risks include hypergastrinemia, chronic kidney disease and even dementia [41]. In addition to health risks, inappropriate PPI use imposes a financial burden. A study involving 2.5 million hospitalized patients in the USA showed that 69% of discharged patients were unnecessarily prescribed PPIs, leading to over $3 million in costs within the first month of treatment [38]. Similarly, studies from Türkiye have reported that PPIs are among the most common potentially inappropriate medications in older adults [8, 31]. In Türkiye, patient appointments are scheduled through a centralized digital system known as the Centralized Doctor Appointment System (CDAS). Due to high demand, appointment durations in outpatient clinics are typically limited to approximately 10 min per patient, contributing to a substantial workload within the healthcare system. As only physicians are authorized to prescribe PPIs in Türkiye, this high patient volume may limit the time available for thorough clinical evaluation and comprehensive patient counseling [2]. Although primary care services are available throughout the country, the system does not allow for adequate patient follow-up, and polypharmacy control remains insufficient, leading to unnecessary PPI use and potential adverse effects [24]. Numerous studies have documented the clinical and financial impact of inappropriate PPIs prescribing. While a few qualitative studies have explored the prescribing practices of general practitioners, little is known about the perspectives of internists, who are frequently involved in initiating and maintaining PPIs therapy [1, 14, 42]. We previously conducted a broader study on physicians’ overall management of PPIs; in this manuscript, we present a focused analysis of their deprescribing behaviors—an area of growing importance given that many patients continue PPIs therapy lifelong without clinical necessity. To explore this topic in depth, we applied the Theoretical Domains Framework (TDF) which provides a comprehensive approach to understanding human behavior by encompassing behavior change theories grouped into 14 domains, including “knowledge, skills, social/professional role and identity, beliefs about capabilities, beliefs about consequences, memory, attention and decision processes, environmental context and resources, social influences, emotion, and behavioral regulation” [5]. Utilizing the TDF to analyze deprescribing behaviors offers valuable insights into the cognitive, social, and environmental factors influencing physicians’ decision-making. The aim of this qualitative study was to explore the beliefs, attitudes and behaviors of internists in Türkiye regarding deprescribing PPIs, using the TDF. Methods Study design We employed a qualitative research design using semi-structured interviews to explore the factors influencing internists’ deprescribing behaviors for PPIs. This study is reported in accordance with the Consolidated Criteria for Reporting Qualitative Research (COREQ) guidelines [39]. Participant recruitment Participants were selected through convenience sampling among internal medicine residents and specialists at a university hospital in Istanbul. This study aimed to include a diverse mix of residents and specialists at different levels of seniority. The interviews were conducted until data saturation was reached, and no further participants were recruited. Data collection Data were collected through in-depth interviews during March and April 2023. Two separate vignettes (Appendix 1), each illustrating common clinic scenarios related to PPI use, were used to stimulate the discussion by exploring their clinical practice regarding PPI management. The first vignette described an adult patient presenting with gastric complaints and was designed to explore participants’ prescribing behavior for initiating PPI therapy. Although our primary analysis in this manuscript focuses on deprescribing, including this vignette provided contextual insight into internists’ overall approach to PPI management. The second vignette focused on deprescribing and featured an older adult with potentially inappropriate PPI use, based on the Turkish Inappropriate Medication use in the Elderly (TIME) criteria [3]. Following the vignettes, a semi-structured interview guide based on the TDF was used to frame the interview questions [5]. The guide is cross-referenced with the TDF to ensure all 14 domains are covered. The draft interview guide was developed by the research team based on a literature review. It was then reviewed and revised by a gastroenterologist and a pharmacologist. A pilot interview was conducted to ensure clarity and relevance, after which the guide was finalized. Reflexivity was addressed through the involvement of researchers from different disciplinary backgrounds. Regular consensus meetings were held to discuss and refine the analysis, allowing for critical reflection on interpretations. All interviews were conducted by two researchers trained in qualitative methods. Interviews were conducted face-to-face at the hospital, only the interviewer and the participant were present at the interview. One interview conducted via telephone. Each interview lasted 20–60 min and was audio-recorded with participants’ consent. Data analysis All interviews were transcribed verbatim and de-identified to ensure confidentiality. The transcripts were imported into Atlas.ti for analysis. A hybrid thematic analysis, combining deductive coding based on the TDF domains with inductive, data‑driven theme development, was conducted, with the TDF used as a guiding framework. The analysis followed a multi-step process. Initially transcripts were independently read line-by-line, and a codebook was developed to categorize responses according to the TDF domains (Appendix 2). Responses within each domain were grouped into themes, defined as clusters of related responses addressing PPI management practices. Relevant domains were identified based on their frequency, the presence of conflicting or strong beliefs, and their potential impact on PPI management. Coding consistency and reliability were ensured through independent coding by three researchers and iterative team discussions to resolve discrepancies. TDF domains represent higher-level theoretical constructs, whereas themes refer to data-driven patterns identified within each domain. All TDF domains were considered during the coding process. Direct quotes from participants were included in the findings to illustrate domains and ensure transparency. Ethical considerations This study was approved by the Marmara University School of Medicine Research Ethics Board (01.04.2022; 09.2022.663). Participants were informed about the study objectives and provided informed consent. Confidentiality was maintained by de-identifying all participant information and securely storing data. Results Twelve participants were enrolled, including ten residents and two specialists, with seven females and five males. Participants were aged 27 to 48 years, with professional experience ranging from 1 to 13 years. This study identified several barriers to internists’ deprescribing of PPIs, including environmental context and resources, reinforcement, social influences, optimism/pessimism, emotions, social/professional role and identity, and knowledge and skills. The enablers were primarily related to intention and goals, as well as memory, attention, and decision-making processes. Beliefs about consequences exhibited a dual impact as a barrier and an enabler. We did not identify themes regarding the beliefs about capabilities and behavioral regulation domains of the TDF. Figure 1 illustrates the 12 TDF domains associated with barriers and enablers to deprescribing PPIs. Fig. 1Themes and TDF domains identified as barriers and enablers to physicians’ deprescribing of PPIs in Türkiye*. *The figure illustrates the identified codes categorised into barriers and facilitators, and related themes for physicians’ deprescribing of PPIs. Red-coloured text corresponds to TDF domains identified as barriers, green-coloured text corresponds to TDF domains identified as enablers, and yellow-coloured text corresponds to TDF domains identified both as barriers and enablers. Gray boxes represent the themes. The higher text size of TDF domains indicates a higher frequency of coding Themes and TDF domains identified as barriers and enablers to physicians’ deprescribing of PPIs in Türkiye*. *The figure illustrates the identified codes categorised into barriers and facilitators, and related themes for physicians’ deprescribing of PPIs. Red-coloured text corresponds to TDF domains identified as barriers, green-coloured text corresponds to TDF domains identified as enablers, and yellow-coloured text corresponds to TDF domains identified both as barriers and enablers. Gray boxes represent the themes. The higher text size of TDF domains indicates a higher frequency of coding Barriers Environmental context and resources Participants emphasized the absence of a coordinated referral and follow-up system within the Turkish healthcare setting. Because patients can access primary, secondary, and tertiary care services without a referral, they often consult multiple physicians at different levels of care. However, these physicians rarely communicate or collaborate effectively, resulting in a fragmented treatment process. This lack of coordination, combined with the ease of prescribing PPIs, was considered as a significant barrier to deprescribing. Furthermore, the healthcare system does not maintain an updated list of patients’ current medications and records of discontinued therapies. As a result, even when one physician discontinued a PPI, another—often a primary care physician—might subsequently re-prescribe it, thereby undermining previous deprescribing efforts.Since patients are often followed by different physicians, the initial indication and the reason for continuing the medication are often unclear. P8, Female, Resident. Since patients are often followed by different physicians, the initial indication and the reason for continuing the medication are often unclear. P8, Female, Resident. Another critical barrier identified was the overcrowded outpatient clinics, where limited time and resources made it difficult to thoroughly assess the necessity of continued PPI use. Participants highlighted that the intense working conditions in hospitals prioritize the number of patients seen over the quality of care, making it nearly impossible to allocate the time needed for effective counseling and patient engagement. Physicians, particularly those working in emergency departments, might prescribe PPIs without comprehensive evaluation. Once initiated, PPIs were often continued during inpatient care, making subsequent deprescribing efforts more challenging.The patient comes straight to the ward with their Panto (pantoprazole), no matter what the diagnosis is. After that, the Panto sticks to the order and nobody questions the indication. I think the biggest problem is that doctors don’t even know why the drug was started in the first place because of the heavy workload. P8, Female, Resident. The patient comes straight to the ward with their Panto (pantoprazole), no matter what the diagnosis is. After that, the Panto sticks to the order and nobody questions the indication. I think the biggest problem is that doctors don’t even know why the drug was started in the first place because of the heavy workload. P8, Female, Resident. Reinforcement The reinforcement domain was grouped into three themes: patient perceptions, influence of authority and lack of quantifiable metrics. Reinforcement - patient perceptions The participants emphasized that successful discontinuation of PPIs largely depended on patients’ ability to implement and sustain necessary lifestyle changes. Patients frequently perceived PPIs as general “gastroprotective” medications and were largely unaware of their potential long-term adverse effects. Participants reported that many patients viewed PPIs as “savior” drugs, leading to a sense of psychological dependency. Participants emphasized the need to address these patient perceptions by increasing public awareness and patient education, particularly regarding the risks of prolonged PPI use. One participant specifically noted that the prevailing “social” perception of PPIs must be actively disrupted to facilitate deprescribing efforts.People seem to have a particular dependence on PPIs, and the reason for this should be questioned. It is necessary to ask the patient whether they perceive it as a rescue drug or in some other way. If this commitment that prevents the patient from discontinuing the drug, then it should definitely be discussed with the patient including from a psychological perspective P3, Male, Resident. People seem to have a particular dependence on PPIs, and the reason for this should be questioned. It is necessary to ask the patient whether they perceive it as a rescue drug or in some other way. If this commitment that prevents the patient from discontinuing the drug, then it should definitely be discussed with the patient including from a psychological perspective P3, Male, Resident. Reinforcement - influence of authority Some participants observed that the professional status or title of the physician could influence the success of deprescribing. They indicated that when a professor-level physician recommended discontinuing a PPIs, patients were more readily convinced compared to when the same advice was given by a general practitioner or a non-academic specialist. This suggests that patients’ acceptance of deprescribing interventions is strongly influenced by the perceived authority or professional status of the physician.… when the professor comes and explains, they’re like ‘okay’ and just go along with it — they get convinced. We say the same things, but I guess because the professor is the professor, it just sounds more authoritative or something, I don’t know. P10, Female, Resident. … when the professor comes and explains, they’re like ‘okay’ and just go along with it — they get convinced. We say the same things, but I guess because the professor is the professor, it just sounds more authoritative or something, I don’t know. P10, Female, Resident. Reinforcement - lack of quantifiable metrics Participants highlighted that adverse effects from PPI use are rarely present with clear, immediate symptoms, and that no routine laboratory tests exist to monitor PPIs-related complications. This lack of overt clinical cues made it even more difficult to persuade patients to discontinue PPIs, further hindering deprescribing efforts.Since we cannot directly see PPIs in a lab test, for example, it is easier to adjust diabetes treatment based on lab results or to regulate hypertension treatment. But with PPIs, there is no lab counterpart, so deprescribing them becomes difficult — on what grounds are we supposed to discontinue them? P10, Female, Resident. Since we cannot directly see PPIs in a lab test, for example, it is easier to adjust diabetes treatment based on lab results or to regulate hypertension treatment. But with PPIs, there is no lab counterpart, so deprescribing them becomes difficult — on what grounds are we supposed to discontinue them? P10, Female, Resident. Social influences Several participants reported that, for many patients, PPIs had been prescribed previously by another physician. As a result, participants expressed hesitation in deprescribing PPIs, even when they believed it was clinically appropriate, due to concerns about contradicting the original prescriber. They noted that deprescribing could potentially create a sense of distrust toward the initial physician and negatively affect the patient–physician relationship, as patients often held strong confidence in the physician who had first prescribed the medication.It is sometimes difficult to challenge what another physician has said. Honestly, if the patient insists persistently, I tend to give in. P7, Male, Specialist. It is sometimes difficult to challenge what another physician has said. Honestly, if the patient insists persistently, I tend to give in. P7, Male, Specialist. The influence of senior physicians and professors also played a significant role in shaping deprescribing practices. Knowledge and clinical habits were often transferred in a top-down manner, and approaches to deprescribing varied depending on the attitudes of senior physicians. While some senior physicians prioritized minimizing unnecessary PPI use, others were more permissive, leading to variability in practice. A few participants highlighted the important role of clinical pharmacists, particularly in intensive care settings, in promoting rational PPI use. Deprescribing was more likely when senior physicians or clinical pharmacists questioned the necessity of continued PPIs therapy.For example, in our ICUs and wards, we have clinical pharmacists who usually alert us, saying things like, ‘Why is this patient taking a PPI? So, we always have a sort of control mechanism. P11, Female, Resident. For example, in our ICUs and wards, we have clinical pharmacists who usually alert us, saying things like, ‘Why is this patient taking a PPI? So, we always have a sort of control mechanism. P11, Female, Resident. Participants reported deprescribing when they perceived no clear indication for continued PPI use, tailoring their decisions to individual patient needs. However, patient attitudes complicated deprescribing efforts. When patients experienced symptom relief with PPIs, they often became reluctant to discontinue the medication and frequently insisted on its refill of prescription. In contrast, if the patients discontinued PPIs inappropriately, they would have rebound acidity. Then, although PPIs are not pharmacologically addictive, patients often had difficulty discontinuing them because the recurrence of symptoms after discontinuation was perceived as a worsening of their condition. Patients were also less motivated to adopt lifestyle changes, as PPIs are perceived as “miracle drugs” that can alleviate their symptoms. In such situations, participants reported struggling to uphold their deprescribing decisions, and many admitted that, faced with patient resistance, they sometimes defaulted to continued prescribing rather than pursuing deprescribing.Patients prefer to continue using the medication rather than implementing lifestyle changes, as they experience active symptoms when the drug is discontinued. P2, Female, Resident. Patients prefer to continue using the medication rather than implementing lifestyle changes, as they experience active symptoms when the drug is discontinued. P2, Female, Resident. Several participants shared specific challenges that complicated deprescribing. One participant noted that the rapid relief of dyspeptic symptoms provided by PPIs could elevate the physician to a “hero” status in the eyes of patients, making discontinuation psychologically difficult for both parties.It’s not something tangible or life-saving, but this symptomatic improvement makes you look like a hero in the patient’s eyes, and some physicians find that rewarding. P4, Male, Resident. It’s not something tangible or life-saving, but this symptomatic improvement makes you look like a hero in the patient’s eyes, and some physicians find that rewarding. P4, Male, Resident. Beliefs about consequences This domain was identified as both a barrier and an enabler. All participants believed that deprescribing inappropriate PPIs would have a positive impact on patient health, primarily by protecting patients from potential adverse effects and also reducing the risk of drug interactions. However, they noted that because many adverse effects do not manifest in the short term, the importance of deprescribing is often overlooked also by physicians. While certain physicians prescribe PPIs as protective agents even without a clear indication, some physicians believed that these are safe drugs and they did not have high concern regarding the potential long-term harms of these medications. Optimism/pessimism and emotions Physicians were generally not optimistic about the feasibility of implementation of PPIs deprescribing practices, citing heavy patient loads and significant time constraints as major barriers. Neither physicians demonstrate the patience required for deprescribing, nor patients alter their established habits. Although participants were aware of the widespread unnecessary use of PPIs, the burden of workload and systemic pressures often left them feeling exhausted and constrained, thereby making deprescribing difficult even when it was clinically indicated.I feel hopeless because quantity is considered rather than quality. As the number of patients increases, the likelihood of a physician making errors also rises; this is a fact. That is why I feel hopeless, because I do not believe that we are prioritizing quality in the current healthcare system. P8, Female, Resident. I feel hopeless because quantity is considered rather than quality. As the number of patients increases, the likelihood of a physician making errors also rises; this is a fact. That is why I feel hopeless, because I do not believe that we are prioritizing quality in the current healthcare system. P8, Female, Resident. Social/professional role and identity Almost all participants agreed that all physicians, regardless of specialty, had a role in deprescribing PPIs and that the use of PPIs should be reviewed at every patient visit, as each encounter represents an opportunity for deprescription. However, most participants emphasized that the primary responsibility for deprescribing—specifically determining when and how to discontinue PPIs—should lie with the physician who initially prescribed the medication.The primary physician who initially started the treatment is always responsible. Why was it started? In other words, the one who decided to start it should also decide when to deprescribe it and follow up accordingly. P1, Male, Resident. The primary physician who initially started the treatment is always responsible. Why was it started? In other words, the one who decided to start it should also decide when to deprescribe it and follow up accordingly. P1, Male, Resident. Participants also highlighted that patient monitoring and long-term management of PPI use should primarily be conducted within primary care settings. Family physicians were perceived as key actors in preventing inappropriate PPI use due to their continuous and close contact with patients. Nevertheless, participants noted that primary care physicians, alongside other healthcare providers, must be able to recognize when referral to specialists, such as internists or gastroenterologists, is necessary for further evaluation.In my opinion, family physicians should primarily monitor, as they have closer and more frequent contact with the patients. P5, Female, Specialist. In my opinion, family physicians should primarily monitor, as they have closer and more frequent contact with the patients. P5, Female, Specialist. Knowledge and Skills Most participants rated their knowledge and skills in PPI management as moderate to adequate. They reported being aware of the indications and potential adverse effects of PPIs and acknowledged that lifestyle modifications should be the primary and initial approach before pharmacological treatment. Although participants expressed a desire to deprescribe PPIs when appropriate, they generally reported insufficient knowledge and skills in deprescribing compared to prescribing practices. Participants also highlighted the existence of a “gray area” regarding when and how to appropriately deprescribe PPIs. Some also emphasized the lack of clear and sufficient guidance to support deprescribing protocols for PPIs.… medical schools unfortunately do not provide instruction on exactly how to use PPIs—such as how to start, adjust, or discontinue them when a patient presents. P4, Male, Resident. … medical schools unfortunately do not provide instruction on exactly how to use PPIs—such as how to start, adjust, or discontinue them when a patient presents. P4, Male, Resident. Enablers Intention, goals and memory, attention and decision processes Despite the various challenges identified, participants described individual efforts to integrate deprescribing practices into their routine clinical work. Participants expressed a clear intention to manage PPI use appropriately, emphasizing their aim to pursue evidence-based deprescribing practices when necessary. Many participants reported that they actively sought to keep themselves updated on PPIs management by reviewing the literature, following recent publications, or attending scientific meetings. Some noted that because clinical rotations often changed the patient populations they encountered, their knowledge regarding PPIs could fade over time. To counteract this, they kept screenshots or quick notes on their phones for easy reference when needed.In internal medicine, I can say that you always need to study. There are notes. I usually have all the notes on my phone, for example. When I forget something, I just open it and check. P6, Female, Resident. In internal medicine, I can say that you always need to study. There are notes. I usually have all the notes on my phone, for example. When I forget something, I just open it and check. P6, Female, Resident. Some residents described using a trial-and-error approach to deprescribe, basing their decisions on patient responses rather than pre-established guidelines.For patients without very obvious symptoms, I usually reduce to a half dose; if there is no increase in complaints during follow-up, I change it to every other day and then plan for complete deprescribing. P1, Male, Resident. For patients without very obvious symptoms, I usually reduce to a half dose; if there is no increase in complaints during follow-up, I change it to every other day and then plan for complete deprescribing. P1, Male, Resident. In older patients with multiple comorbidities, participants often experienced clinical hesitation toward deprescribing, concerned about destabilizing the patient’s condition.For patients with only dyspeptic complaints, I might consider reducing and deprescribing PPIs. I am able to stop the drug. However, for older patients with multiple comorbidities who use many drugs, such as antiplatelet agents, I am hesitant [to deprescribe]. P10, Female, Resident. For patients with only dyspeptic complaints, I might consider reducing and deprescribing PPIs. I am able to stop the drug. However, for older patients with multiple comorbidities who use many drugs, such as antiplatelet agents, I am hesitant [to deprescribe]. P10, Female, Resident. Several participants also highlighted the economic burden associated with inappropriate PPI prescriptions as an enabler for deprescribing of PPIs. They suggested that implementing deprescribing strategies could not only improve patient safety but also contribute to reducing unnecessary healthcare expenditures.You prevent additional harm caused to the patient and reduce costs, as these medications are widely dispensed—like sugar—in pharmacies today, creating a significant financial burden for the state. P4, Male, Resident. You prevent additional harm caused to the patient and reduce costs, as these medications are widely dispensed—like sugar—in pharmacies today, creating a significant financial burden for the state. P4, Male, Resident. Discussion In this study, we explored internists’ experiences with deprescribing PPIs in Türkiye. Based on the TDF analysis, this study identified several barriers to internists’ deprescribing of PPIs, including environmental context and resources, reinforcement, social influences, beliefs about consequences, optimism/pessimism, emotions, social/professional role and identity, and knowledge and skills. The enablers were primarily related to intention and goals, as well as memory, attention, and decision-making processes and beliefs about consequences. Key barriers included a fragmented healthcare system, heavy workload, poor coordination among providers, and patients’ strong expectations of PPIs as “rescue” drugs. Social influences, such as the authority of senior physicians and trust in the initial prescriber, further complicated decisions. Despite these challenges, participants showed intention to deprescribe and used practical strategies like dose tapering, while emphasizing the need for clearer guidance and training. Internists’ deprescribing behaviors were influenced by a lack of integrated care, national guidelines, patient-centered care approaches and individual-level factors. Lack of integrated care Deprescribing is a multifaceted process, and as highlighted in previous studies, multiple barriers exist alongside potential facilitators [25]. Systemic problems in the healthcare system are the main barriers to successfully deprescribing PPIs. Participants emphasized the lack of coordination between healthcare providers, the overcrowding of outpatient clinics, and the short consultation times, which hinder physicians from defining patient-specific goals or prioritizing deprescribing efforts. The heavy workload and time constraints result in physicians prioritizing severe health concerns, while inappropriate PPI use remains unaddressed. These systemic barriers prevent the implementation of the basic deprescribing steps, such as taking a comprehensive medication history, identifying potentially inappropriate medicines, and selecting suitable patients for discontinuation [32]. In Türkiye, the healthcare system is organized into primary, secondary, and tertiary levels, with a family physician model in place since 2011; however, the referral system has not been effectively implemented [35]. This leads patients to consult multiple physicians across different levels of care without adequate communication, resulting in fragmented treatment efforts. Also, the lack of an integrated medication record means that discontinuation decisions are not visible to other providers, allowing PPIs to be re-prescribed and undermining deprescribing efforts. Under these circumstances, deprescribing PPIs becomes nearly impossible. As participants expressed, addressing these structural barriers will require systemic reform. Appropriate medication use and successful deprescribing can only be achieved within an effective and well-coordinated healthcare system [19, 20, 22, 27]. Many physicians acknowledged that their deprescribing practices were shaped more by their mentors’ habits than by evidence-based protocols. Professional hierarchy and inter-professional collaboration thus emerged as important factors. While the supportive attitude of seniors was seen as a facilitator, differences in practice among mentors created confusion and highlighted the absence of standardized approaches. Previous studies have shown that non-physicians, such as pharmacists and nurses, can also play a supportive role in the deprescribing process [6, 9, 29]. While the influence of nurses was not explicitly captured in this study, the presence of a clinical pharmacist in the hospital was described as a facilitator, consistent with studies demonstrating the positive role of pharmacists in deprescribing [11], (McNicholl et al., 2014). Multidisciplinary teams may be key to facilitating PPI deprescribing in both hospital and primary care settings [10,16, 43]. Strengthening the integration of non-physician healthcare professionals within clinical settings could further improve outcomes as part of an integrated care approach [21]. The findings of this study support the involvement of multidisciplinary teams in the process of PPIs Deprescribing. Since 2018, a small number of clinical pharmacists have started working in clinics in Türkiye [17]. This identified supportive impact could be considered a significant finding that warrants further consideration. Participants also recognized the economic burden of unnecessary PPI use for the healthcare system. In Türkiye, all citizens are covered by national health insurance, and patients can still access PPIs easily. This contributes to repeated and prolonged PPI use [25]. Recently, the Turkish Ministry of Health issued a directive aimed at reducing inappropriate prescribing including PPIs (MoH, 2024). This represents an important step toward both minimizing patient exposure to unnecessary medications and reducing the financial burden on the government. The initiative targets primarily family physicians, signaling a step toward broader policy interventions. Lack of implemented evidence-based clinical practice Despite being aware of the appropriate indications for PPIs, physicians in this study reported limited knowledge and skills in implementing deprescribing. They relied heavily on personal judgment, in the absence of national or institutional guidelines. Clinical experience, rather than evidence-based resources, appeared to dominate decision-making. As physicians described a lack of “cues to action” in daily practice, they believed that existing clinical protocols for deprescribing were insufficient to guide clinical practice [18]. Although evidence-based international guidelines for PPI deprescribing are available, participants in our study perceived a lack of national guidelines providing practical guidance in their clinical context, suggesting an implementation gap. As expressed by the participants, physicians need structured deprescribing guidelines to strengthen their practice [25, 30]. Physicians also highlighted a striking barrier: the absence of routine laboratory markers or measurable outcomes to demonstrate PPI-related harm. Even though routine laboratory tests are generally not required to support PPI deprescribing, the lack of quantifiable metrics in increasingly digitalized healthcare systems may undermine deprescribing practices. This situation may also adversely affect the physician–patient relationship. Physicians also reported dilemmas in deprescribing decisions, as these could generate patient distrust toward the initial prescriber, particularly when their own recommendations contradicted the original advice. This hesitation likely arises from physicians’ concern about undermining their colleagues or compromising the physician–patient relationship. The absence of clear deprescribing implementation initiatives may contribute to this indecisiveness. Identifying implementation barriers and selecting appropriate strategies may help promote the effective implementation of deprescribing practices in daily practice [28]. Lack of patient centered care Given the complexity of deprescribing, it is unlikely that a single universal intervention will succeed. However, patient-centered interventions (including patient education and counselling sessions to promote shared decision making, patient leaflets) remain feasible [4, 12, 30, 40]. Identifying the underlying reasons for patients’ behaviors is fundamental for effective deprescribing. Personalized theory-based interventions should be developed and implemented to promote deprescribing PPIs. Providing physicians with a supportive working environment enables more effective communication with their patients, which is essential for optimal care. Another important barrier arose from patients’ insufficient understanding of PPI use and risks. PPIs are widely perceived as “stomach protectors” or “savior” drugs. This belief contributes to resistance when deprescribing is suggested. Because PPIs are generally well-tolerated and adverse effects are rarely apparent, patients seldom perceive them as harmful. However, PPIs are not entirely harmless drugs, therefore lifestyle modifications should be considered prior to prescribing [15]. Since effective physician–patient communication has been shown to improve deprescribing outcomes, addressing and modifying patient beliefs is critical [40]. However, appropriate consultation conditions, including adequate time, must be in place to achieve this. These challenges again highlight the need for systemic reforms in the healthcare system to facilitate effective deprescribing. Providing patient education and counselling sessions with relevant resources would be useful to overcome barriers related to patients’ beliefs about PPIs [7]. Future studies The findings of this study provide evidence to design behavior change interventions that are calibrated to the professional and cultural environment in the Turkish healthcare system. To facilitate effective implementation, it was vital to uncover the context-specific barriers in Turkiye and a tailored selection of Behavior Change Techniques (BCTs) can be applied to address the specific needs identified [37]. Strengths and limitations of the study Given the qualitative design, the results are not generalizable, and the study’s scope was further limited by being conducted in a single hospital. Conducting the research in a tertiary teaching hospital may also have influenced the findings, as clinical decision-making in such settings can be more complex than in primary care. This study design may also have introduced social desirability bias. Transcripts were not returned to participants for comment and/or correction. Consequently, participants did not have the opportunity to review or confirm the findings. Since the study did not employ data triangulation, our results are based solely on self-reported measures. Despite these limitations, the study provides useful insights into deprescribing practices from the perspective of internists, a group less frequently studied than general practitioners. We sought to enhance the trustworthiness of our findings. For credibility, interviews were conducted by researchers trained in qualitative methods who were not involved in clinical practice or prescribing, and there was no supervisory relationship with participants. To support transferability, we described the context, health‑care system, and sampling strategy in detail so that readers can judge applicability to other settings. Dependability was strengthened by systematically documenting methodological decisions and use of the TDF framework. Conclusion Deprescribing represents a valuable intervention; however, it is hindered by barriers related to physicians, patients, and the healthcare system. Identifying the underlying causes of patient behavior is essential, and interventions should be tailored accordingly. To promote deprescribing, appropriate BCTs and implementation strategies should be identified and evaluated to ensure integrated care, evidence-based guidelines, and patient-centered practice. Patient education and counseling should be prioritized, while physicians’ knowledge and skills must be strengthened. In this regard, national deprescribing guidelines should be developed, and existing international guidelines adapted to local contexts. Enhancing the physician–patient relationship is critical, and providing physicians with supportive working environments would foster more effective communication and deprescribing. The findings highlight the need for systemic reforms, supported by national policy initiatives, to reduce inappropriate PPI use and promote rational prescribing practices. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2